The Federal Commission for the Protection against Sanitary Risks (Cofepris) ordered the immobilization and non-commercialization of the raw material and all medicines containing Valsartan from the Chinese manufacturer Zhejiang Huahai Pharmaceutical due to quality defect.
Cofepris ordered the recall of medicines containing the active ingredient Valsartan, which is manufactured by the Chinese company after it launched an international notification on the detection of an impurity generated by product synthesis.
Valsartan is the active ingredient present in medicines that are used for the treatment of heart failure as well as an antihypertensive agent.
The identified products, so far, containing the raw material of the manufacturer Zhejiang Huahai Pharmaceutical are:
1.- Diovalte, de Química y Farmacia SA de CV
2.- Vapispre, by Laboratorios Pisa SA de CV
3.- Avalraam, by Laboratorios Raam de Sahuayo SA de CV
4.- Menfhipress, of Farmacéutica Hispanoamericana SA de CV
5.- Versalver, de Productos Maver SA de CV
6.- Vagsar, of Novag Infancia SA de CV
The Commission suggests that patients who have the medication at home contact the laboratory in order to determine the return policy.
Those who use drugs containing Valsartan are told to not suspend treatment, but are to go to the doctor for an alternative prescription.
The recommendation for doctors is to review the treatments and replace the medication with another with the same composition or therapeutic indication .
For more information, he provided telephones 50805200 Ext. 1391, 1256, 4257, 1183 and email firstname.lastname@example.org.